• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Will the Trump Administration Regenerate the Health Care Bill?

    Bryan Mc Govern
    Apr. 04, 2017 02:53PM PST
    Pharmaceutical Investing
    Pharmaceutical Investing

    After vowing to repeal Obamacare last month, Trump’s administration is now seeking a deal on a new health care bill.

    On Monday (April 2), White House officials, including Vice President Mike Pence, offered a new version of the failed GOP health-care plan to appease far-right Republicans.
    According to Bloomberg, House Speaker Paul Ryan said on Tuesday there isn’t a bill text or an agreement just yet. On the other hand Mark Walker, chairman of the conservative Republican Study Committee said it is being put together.
    That said, an initial vote on the floor was set to take place on March 24 but, just before the voting went down, President Donald Trump asked speaker Paul Ryan to pull the bill.
    “Obamacare’s the law of the land. It’s gonna remain the law of the land until it’s replaced. We did not have quite the votes to replace this law… we’re gonna be living with Obamacare for the foreseeable future,” said Ryan in a press conference following the defeat of his bill.


    The new bill would allow states to apply for waivers for requirements on insurance companies under the affordable care act, according to the AP. One of those requirements prohibits insurance companies from declining to ensure people with serious diseases.
    Before accepting the offer, Freedom Caucus members said they would prefer to see it in writing.
    One of the key challenges the initial bill faced, besides complete dismissal from Democrats, was the lack of support from the Freedom Caucus, an ultra-right group that didn’t see the bill fully repealing Obamacare.
    White House spokesperson Sean Spicer said the administration feels “very optimistic” about the discussions taking place regarding the bill and expects a resolution by the end of the week.
    “Right now, we’re just at that conceptual stage about how to move forward in a way that can get everybody to 216,” Ryan told reporters today. The bill needs 216 votes in Congress so it may move on to the Senate.
    “The administration is saying it would like it this week,” Bloomberg quoted Republican Representative Chris Collins of New York as saying. 
    Following the failure of the original bill, president Trump tweeted the Freedom Caucus needed to “get on the team” otherwise they would hurt the entire Republican agenda, threatening to even challenge them in the Senate election next year.
    On that note, the market reacted negatively to the failure of the original health-care bill. Despite the possibility for a GOP care plan to pass, the unpredictability of Trump’s presidency has proven to take a hit to the market, especially when he uses Twitter as a platform to attack groups or industries from tweets.
    Don’t forget to follow us @INN_LifeScience for real-time news updates!
    Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
    health carepharmaceutical investingpaul ryandonald trumpfreedom caucusaffordable care act
    The Conversation (0)

    Go Deeper

    AI Powered
    Bitcoin with US flags.

    How Will Trump's US Election Win Affect the Crypto Industry?

    Test tubes.

    Biotech Market Forecast: Top Trends for Biotech in 2025

    Latest News

    Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

    IVX:AU

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×